Regeneron Pharmaceuticals (NASDAQ:REGN) Stock: Insider Christine Poon Sells 7,830 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Christine Poon sold 7,830 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the transaction, the director owned 5,219 shares of the company’s stock, valued at $5,057,680.71. This represents a 60.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded down $42.69 during mid-day trading on Wednesday, hitting $930.67. The stock had a trading volume of 1,383,115 shares, compared to its average volume of 830,923. The stock has a market capitalization of $95.82 billion, a price-to-earnings ratio of 20.55, a P/E/G ratio of 1.51 and a beta of 0.10. The company has a 50 day simple moving average of $798.74 and a 200-day simple moving average of $740.16. Regeneron Pharmaceuticals, Inc. has a 52 week low of $591.52 and a 52 week high of $991.73. The company has a current ratio of 3.35, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. During the same period in the previous year, the business posted $11.83 EPS. Regeneron Pharmaceuticals’s revenue was up 36.3% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be given a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is currently 8.30%.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently modified their holdings of REGN. Kestra Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 2.4% during the third quarter. Kestra Investment Management LLC now owns 675 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 16 shares in the last quarter. AlphaCore Capital LLC grew its stake in shares of Regeneron Pharmaceuticals by 133.5% in the 3rd quarter. AlphaCore Capital LLC now owns 1,602 shares of the biopharmaceutical company’s stock valued at $1,215,000 after purchasing an additional 916 shares during the period. Leuthold Group LLC grew its stake in shares of Regeneron Pharmaceuticals by 11.2% in the 3rd quarter. Leuthold Group LLC now owns 10,303 shares of the biopharmaceutical company’s stock valued at $7,812,000 after purchasing an additional 1,038 shares during the period. Fulcrum Asset Management LLP acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $519,000. Finally, StoneRidge PMG Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $610,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Zacks says improving earnings estimates could help support further near-term gains in REGN shares, following the stock’s recent advance. Why Regeneron Might Be Well Poised for a Surge
• Positive Sentiment: Analysts have raised price targets and several firms have expressed confidence in further appreciation. This follows Regeneron’s strong third-quarter results: revenue rose 36.3% year over year to $5.12 billion and EPS of $20.07 beat consensus of $16.51. Coverage also cited commercial performance and pipeline progress. RBC raises its price target Cantor Fitzgerald outlook Q3 results and pipeline coverage
• Neutral Sentiment: Director Kathryn Guarini sold 400 shares for $360,000 under a pre-arranged Rule 10b5-1 plan. The planned sale is less informative as a signal about the company’s outlook. Director share sale
• Negative Sentiment: The recent rally may leave room for valuation-related caution: some analyst targets remain below the share price, even as other firms have lifted their forecasts. The articles do not identify a fresh company-specific setback behind Wednesday’s weakness.

Analysts Set New Price Targets

A number of brokerages have recently commented on REGN. Raymond James Financial raised their price target on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Canaccord Genuity Group upped their price objective on shares of Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Wells Fargo & Company increased their target price on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the company an “equal weight” rating in a research report on Monday. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 20th. Finally, JPMorgan Chase & Co. raised their target price on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $898.97.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.